본문으로 바로가기

산업동향

Presodemt Obama, The 111 TH Congress, and Biotechnology : Working Together Today to Ensure a Healthy Tomorrow

  • 등록일2009-03-27
  • 조회수7292
  • 분류산업동향 > 종합 > 종합
  • 자료발간일
    2009-01-27
  • 출처
    A Massachusetts Biotechnology Council
  • 원문링크
  • 키워드
    #Obama#생명공학#Biotechnology#오바마
  • 첨부파일
Presodemt Obama, The 111TH Congress, and Biotechnology :
Working Together Today to Ensure a Healthy Tomorrow
 
 

FEDERAL POLICY AND THE BIOTECHNOLOGY INDUSTRY - AN INTRODUCTION
 

Government leaders in the United States have long held an avid interest in biotechnology, and with good reason. By harnessing breakthroughs in advanced biology and chemistry to innovative processes for developing and manufacturing products, biotechnology is positioned to deliver solutions for problems policy makers engage in every day, such as disease, hunger, pollution and the energy crisis.

There are other compelling reasons why Washington should care about biotechnology:
  • It is one of the few major industrial sectors that our nation presently dominates, with
    threequarters of global biotech research and investment and more than half its
    manufacturing occurring in the United States.
  • US biotech revenues constitute 76% of global biotech revenues. ($48 b of $63 b)
  • The average annual salary in the biotech industry is $72K, 86% higher than the average
     US private sector wage
  • The US biosciences community (public and private) employs 1.2 million people directly
     and another 5.8 million indirectly.

Biotechnology in turn is intently interested in government. From the laboratory bench to the patient bedside, biotechnology is heavily regulated by and closely interacts with government each step of the way, as the sector undertakes the long arduous task of commercializing basic academic research.

Because biotechnology is a sector that is involved with the health and well-being of humans and other living things, we recognize that government has an appropriate role to play in the oversight of our industry. Indeed, this industry is unique in that it has consistently called for stronger and more sensible authority and increased funding for its lead regulator, the Food and Drug Administration (FDA). We all benefit from a system committed to the rigorous, science-based review and timely approval of cuttingedge products that are safe, effective, and address unmet medical and/or other socio-economic needs.

On the other hand, there are no benefits from laws and regulations that discourage and stifle
innovation, make it difficult for scientists to pursue discovery, impede companies’ ability to raise the massive amounts of capital needed to commercialize promising research, preclude patient access to state-of-the art therapies or that otherwise detract from biotechnology’s ability to perform and meet its maximum potential.

Fortunately, this is a sector that was built with the help of visionary public policies, factors still widely recognized and understood more than a quarter of a century after biotechnology’s birth. From the groundbreaking Bayh–Dole Act to the doubling of the National Institutes of Health’s (NIH) budget, from passage of the Orphan Drug Act to creation of the Medicare Part D drug benefit, the best policies have sought both to promote innovation and to share as widely as possible the fruits of American scientific ingenuity and commercial enterprise.

Let us continue to journey together down avenues of hope and innovation, guided by humane and visionary leaders committed to sound public policy. We look forward to working with President Obama, the 111th Congress, their staffs, the American people and all other stakeholders to realize our mutual goals for the common good.
 
 
☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.
 
 
 

 
목록 스크랩
관련정보

지식

동향

발간물

자료 추천하기

받는 사람 이메일
@
메일 내용